Leronlimab

DRUG4 trials

Sponsors

CytoDyn, Inc., Hospital Israelita Albert Einstein

Conditions

COVID-19 PneumoniaMetastatic Triple-Negative Breast CarcinomaSolid Tumor, Adult

Phase 2

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

CompletedNCT04504942

CytoDyn, Inc.Solid Tumor, Adult

Start: 2020-05-01End: 2025-01-27Updated: 2026-01-23

Phase 3

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

SuspendedNCT04901689

Hospital Israelita Albert EinsteinCOVID-19 Pneumonia

Start: 2021-10-23End: 2023-02-28Target: 316Updated: 2022-04-15

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

SuspendedNCT04901676

Hospital Israelita Albert EinsteinCOVID-19 Pneumonia

Start: 2021-09-09End: 2023-02-28Target: 612Updated: 2022-04-15

Unknown Phase

A Compassionate Use Study of Leronlimab in Breast Cancer

CytoDyn, Inc.Metastatic Triple-Negative Breast Carcinoma

Updated: 2025-07-15

Related Papers

Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.

Journal of Clinical Oncology2026-05-28

Abstract B019: CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC.

Cancer Immunology Research2025-09-24

Abstract CT156: Changes in circulating tumor associated cells predicts progression free and overall survival in metastatic TNBC patients after induction of the anti-CCR5 drug leronlimab

Cancer Research2022-06-151 citations

Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (Leronlimab): A pooled analysis of three clinical trials in patients with mTNBC.

Journal of Clinical Oncology2022-06-0111 citations